Search results for "Platelet-activating factor"

showing 5 items of 15 documents

Activation of macrophages by platelet activating factor (PAF)

1983

Pharmacologymedicine.medical_specialtyAllergyPlatelet-activating factorImmunologyPharmacology toxicologyPharmacologyToxicologymedicine.diseaseRheumatologychemistry.chemical_compoundchemistryInternal medicinemedicinePharmacology (medical)Agents and Actions
researchProduct

LAAE-14, a new in vitro inhibitor of intracellular calcium mobilization, modulates acute and chronic inflammation.

2003

Abstract A new lipidic acid-amido ether derivative (LAAE-14) able to reduce dose-dependently the calcium increases mediated either by calcium ionophore ionomycin, by the endoplasmic reticular Ca 2+ -ATPase inhibitor thapsigargin, or by the chemotactic tripeptide N -formyl- l -methionyl- l -leucyl- l -phenylalanine (fMLP), in human neutrophils as well as in murine peritoneal macrophages, but not ATP, has been evaluated as a potential anti-inflammatory drug. This compound attenuated leukocyte activation by means of its inhibitory effect on the respiratory burst elicited in both types of cells by 12- O -tetradecanoyl phorbol 13-acetate, by inhibition of the degranulation process induced by cyt…

ThapsigarginNeutrophilschemistry.chemical_elementCalciumPharmacologyCarrageenanBiochemistryLeukotriene B4Calcium in biologyDinoprostonechemistry.chemical_compoundMiceCell MovementAnimalsEdemaHumansCytochalasin BNitritesPharmacologyInflammationPlatelet-activating factorPancreatic ElastaseTumor Necrosis Factor-alphaZymosanArthritis ExperimentalRatsDisease Models AnimalchemistryBiochemistryIonomycinAcute DiseaseChronic DiseaseLuminescent MeasurementsPhorbolMacrophages PeritonealTumor necrosis factor alphaCalciumBiochemical pharmacology
researchProduct

Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs.

1993

Abstract Rolipram (0·1–1000 μg kg−1, i.v.) reduced the increase in microvascular permeability induced by platelet-activating factor (PAF; 50 ng kg−1, i.v.) at different sites of the guinea-pig airways. Rolipram (1–100μg kg−1, i.v.) inhibited histamine (30μg kg−1, i.v.)-and bradykinin (0·3 μg kg, i.v.)-induced airway microvascular leakage. These effects of rolipram were obtained at doses which inhibit histamine (7–20 μg kg−1 min−1)-induced bronchoconstriction (IC50 = 3 ± 1 μg kg, i.v.) without depressing arterial blood pressure in the guinea-pig. Aminophylline (50 mg kg−1) did not change the effect of PAF. The anti-exudative effect of rolipram is of potential therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsPharmaceutical ScienceBradykininVascular permeabilityBlood PressureBronchiBradykininCapillary Permeabilitychemistry.chemical_compoundInternal medicinemedicineAnimalsDrug InteractionsPlatelet Activating FactorRolipramPharmacologyPlatelet-activating factorMicrocirculationAminophyllinePyrrolidinonesTracheaEndocrinologymedicine.anatomical_structurechemistryBronchoconstrictionAminophyllinemedicine.symptomRolipramHistaminemedicine.drugBlood vesselEvans BlueHistamineThe Journal of pharmacy and pharmacology
researchProduct

ROLIPRAM INHIBITS PAF-INDUCED AIRWAY MICROVASCULAR LEAKAGE IN GUINEA-PIG - A COMPARISON WITH MILRINONE AND THEOPHYLLINE

1992

The effects of 3 phosphodiesterase (PDE) inhibitors, rolipram (PDE IV), milrinone (PDE III) and theophylline (non-selective) on PAF (50 ng kg-1; iv)-induced airway vascular leakage have been evaluated in guinea-pigs. Rolipram (3-300 micrograms kg-1; iv) reduced the increase in permeability induced by PAF at all airway levels whereas milrinone (10-1000 micrograms kg-1; iv) and theophylline (30 mg kg-1; iv) were without effects. The anti-leakage activity of rolipram may be of therapeutic value in asthma.

medicine.medical_specialtyPhosphodiesterase InhibitorsPyridonesGuinea PigsRespiratory SystemVascular permeabilityCapillary Permeabilitychemistry.chemical_compoundTheophyllineInternal medicinemedicineAnimalsPharmacology (medical)TheophyllinePlatelet Activating FactorRolipramPharmacologybiologyCyclic nucleotide phosphodiesterasePlatelet-activating factorbusiness.industryPhosphodiesterasePyrrolidinonesEndocrinologychemistryEnzyme inhibitorbiology.proteinMilrinonebusinessRolipramEvans BlueMilrinonemedicine.drug
researchProduct

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.

2003

Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the platelet-activating factor-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome (ACS). Individuals within the highest quartile of PAF-AH activity had an 1.8-fold increase in CAD risk [95% confidence interval (CI), 1.01 to 3.2; P = 0.…

platelet-activating factorAdultMaleRiskmedicine.medical_specialtyAcute coronary syndromePAF acetylhydrolaseStatinCross-sectional studymedicine.drug_classMutation MissenseInflammationAngiotensin-Converting Enzyme InhibitorsQD415-436Coronary Artery DiseaseBiochemistryCoronary artery diseaseEndocrinologySex FactorsRisk FactorsInternal medicinemedicineHumansAgedInflammationbusiness.industryCell BiologySyndromeMiddle Agedmedicine.diseaseConfidence intervalCross-Sectional StudiesQuartile1-Alkyl-2-acetylglycerophosphocholine EsteraseAcute DiseaseCardiologylipids (amino acids peptides and proteins)Femaleatherosclerosismedicine.symptombusinessJournal of lipid research
researchProduct